Too-big pharma

10 January 2017 By Robert Cyran

Drugmakers spend $50 bln a year on R&D, but the payoff keeps declining. The projected return for the dozen biggest-spending companies is now less than 4 pct, according to Deloitte. Valeant tried to slash outlays and jack up prices. But it went too far and made things worse.

This content is for Subscribers only

To access full content you must be a subscriber. Please use the following link to request a trial.


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)